June 15, 2015
Cosentyx meets the primary endpoints
Cosentyx (secukinumab) met the primary endpoints of superiority compared to placebo in patients with difficult-to-treat psoriasis of the nails, palms…
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
June 15, 2015
Novartis: Long -term disease control for polycythemia vera patients treated with Jakavi
Novartis announced data that show majority of patients with polycythemia vera treated with Jakavi achieved long-term disease control. The company said…
June 7, 2015
Xolair treats CSU patients better than placebo
Novartis reports new analysis showing Xolair® improving quality of life by 78% for chronic spontaneous urticaria patients New analysis from…